Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: March 15, 2012
Reporting Period: The filing announces financial results for the three months and the full year ended December 31, 2011.
Key Financial Metrics
The provided text serves as a cover report referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity.
Note: Specific financial metrics are not present in the source text provided.
Material Changes
The filing does not detail specific material changes or comparative figures versus prior periods within the text body. It solely references the issuance of a press release containing the results.
Guidance, Outlook, and Risks
Management Commentary: The report confirms the issuance of a press release regarding financial results but does not include specific management commentary, guidance, or outlook in the text provided.
Risks and Contingencies: No specific risks or contingencies are detailed in this excerpt.
Unusual Items: None identified in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 15, 2012) for actual revenue, net loss, and cash position figures.
- Verify the specific clinical trial progress or regulatory updates mentioned in the full press release, as this is a biopharmaceutical company.
- Confirm the company's cash runway and burn rate from the detailed financial statements referenced in the exhibit.